Quantcast

Optimer Pharmaceuticals and Clinical Investigators to Present Data at Upcoming Medical Meetings

April 28, 2011

SAN DIEGO, April 28, 2011 /PRNewswire/ — Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) announced that additional data from the DIFICID(TM) Phase 3 trials will be presented at the following medical meetings:


    Digestive Disease Week (DDW), McCormick Place, Chicago, IL
    May 7-10, 2011

    Poster Presentation Information:
                     Risk of Recurrence and Time to Recurrence Following
    Title:           Treatment of Clostridium
                     difficile Infection: Patient Characteristics and the
                     Differential Effect of Fidaxomicin
                    vs. Vancomycin
    Presenter:      Kathleen M. Mullane, D.O.
    Date:           Saturday, May 7, 2011
    Time:           12:00 p.m. to 2:00 p.m. Central Time
    Location:       Poster Session Hall A (MCP)
                     Intestinal Disorders: Prebiotics, Probiotics and
    Session:         Pathogens
    Program #:      Sa1981

    Poster Presentation Information:
                     High Fecal and Low Plasma Levels of Fidaxomicin and
    Title:           Metabolite OP-1118 in
                     Patients with C. difficile infection:  Combined
                     Results of Two Phase 3 Trials
    Presenter:      Pamela S. Sears, Ph.D.
    Date:           Monday, May 9, 2011
    Time:           12:00 p.m. to 2:00 p.m. Central Time
    Location:       Poster Session Hall A (MCP)
    Session:        Randomized Controlled Clinical Trials
    Program #:      Mo1160

    European Congress of Clinical Microbiology and Infectious Diseases
     and International Congress of Chemotherapy, Milano Convention
     Center, Milan, Italy
    May 7-10, 2011

    Oral Presentation Information:
                     Immunosuppression and the Risk of Death, Cure Rates
    Title:           and Disease Recurrence
                    Among Patients with Clostridium difficile Infection
    Presenter:      Yoav Golan, M.D., M.S.
    Date:           Tuesday, May 10, 2011
    Time:           10:36 a.m. to 10:48 a.m. Central European Time
    Location:       Lecture Hall Brown 1
    Oral Session:   C. difficile News
    Presentation
     #:             O504

    Poster Presentation Information:
                     Clostridium difficile Recurrence, Alcohol
    Title:           Consumption, and the Effect of
                    Fidaxomicin vs. Vancomycin
    Presenter:      Yoav Golan, M.D., M.S.
    Date:           Tuesday, May 10, 2011
    Time:           12:30 p.m. to 1:30 p.m. Central European Time
    Location:       Poster Area Hall 5
    Poster Topic
     99:            Clostridium difficile
    Poster ID#:     P1968

    2011 Annual Scientific Meeting of the American Geriatrics Society
     (AGS), The Gaylord National Hotel, National Harbor, Maryland
    May 11-14, 2011

    Poster Presentation Information:
                     Effect of Advancing Age on Outcomes of Therapy for
    Title:           Clostridium difficile Infection
    Presenter:      Thomas J. Louie, M.D.
    Date:           Thursday, May 12, 2011
    Time:           4:30 p.m. to 6:00 p.m. Eastern Time
    Session:        Presidential Poster Session B
    Location:       Exhibit Hall
    Poster ID#:     B126

About Optimer Pharmaceuticals

Optimer Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing innovative hospital specialty products that have a positive impact on society. Optimer has two anti-infective product candidates in development, DIFICID(TM) (fidaxomicin) and Pruvel(TM) (prulifloxacin). DIFICID is a narrow spectrum antibiotic being developed for the treatment of Clostridium difficile infection (CDI). The FDA granted the Company’s request for six-month Priority Review of Optimer’s NDA for DIFICID, and has assigned a Prescription Drug User Fee Act (PDUFA) goal date of May 30, 2011. The Company also filed a MAA with the European Medicines Agency (EMA) for DIFICID. Pruvel(TM) is a prodrug in the fluoroquinolone class of antibiotics being developed as a treatment for infectious diarrhea. Additional information can be found at http://www.optimerpharma.com.

Contacts

Optimer Pharmaceuticals, Inc.
Christina Donaghy, Corporate Communications Manager
John D. Prunty, Chief Financial Officer & VP Finance
858-909-0736

Canale Communications
Jason I. Spark, Senior Vice President
619-849-6005

SOURCE Optimer Pharmaceuticals, Inc.


Source: newswire



comments powered by Disqus